THE WOODLANDS, Texas, Jan. 12, 2009 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1031, the company’s oral drug candidate for irritable bowel syndrome (IBS). Lexicon has three additional drug candidates progressing through various stages of clinical development, including LX1032 for carcinoid syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes.
